Sarepta Therapeutics Financial Statements (SRPT)
|
|
|
|
Report date
|
|
|
26.02.2020 |
01.03.2021 |
01.03.2022 |
28.02.2023 |
28.02.2024 |
|
06.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
380.8 |
540.1 |
701.9 |
933.0 |
1 243 |
|
1 640 |
|
Operating Income, bln rub |
|
|
-522.3 |
-564.2 |
-449.7 |
-536.2 |
-267.8 |
|
81.0 |
|
EBITDA, bln rub |
? |
|
-652.7 |
-453.4 |
-306.1 |
-582.1 |
-439.2 |
|
153.4 |
|
Net profit, bln rub |
? |
|
-715.1 |
-554.1 |
-418.8 |
-703.5 |
-536.0 |
|
121.8 |
|
|
OCF, bln rub |
? |
|
-456.5 |
107.5 |
-443.2 |
-325.3 |
-501.0 |
|
-352.5 |
|
CAPEX, bln rub |
? |
|
62.7 |
82.2 |
38.5 |
30.8 |
76.1 |
|
117.9 |
|
FCF, bln rub |
? |
|
-519.2 |
25.3 |
-481.7 |
-356.2 |
-588.3 |
|
-470.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
846.6 |
1 041 |
1 055 |
1 329 |
1 361 |
|
1 320 |
|
Cost of production, bln rub |
|
|
56.6 |
63.4 |
97.0 |
140.0 |
150.3 |
|
239.7 |
|
R&D, bln rub |
|
|
560.9 |
722.3 |
771.2 |
877.1 |
877.4 |
|
788.1 |
|
Interest expenses, bln rub |
|
|
30.7 |
59.9 |
63.5 |
53.2 |
22.0 |
|
19.2 |
|
|
Assets, bln rub |
|
|
1 823 |
2 985 |
3 148 |
3 128 |
3 265 |
|
3 600 |
|
Net Assets, bln rub |
? |
|
818.2 |
761.8 |
928.0 |
385.0 |
859.3 |
|
1 221 |
|
Debt, bln rub |
|
|
729.6 |
1 073 |
1 138 |
1 617 |
1 397 |
|
1 398 |
|
Cash, bln rub |
|
|
1 125 |
1 939 |
2 116 |
1 989 |
1 676 |
|
1 198 |
|
Net debt, bln rub |
|
|
-395.1 |
-865.7 |
-977.5 |
-372.0 |
-279.4 |
|
199.2 |
|
|
Ordinary share price, rub |
|
|
129.0 |
170.5 |
90.1 |
129.6 |
96.4 |
|
78.0 |
|
Number of ordinary shares, mln |
|
|
73.6 |
78.0 |
81.3 |
87.6 |
92.4 |
|
95.4 |
|
|
Market cap, bln rub |
|
|
9 499 |
13 291 |
7 318 |
11 346 |
8 910 |
|
7 440 |
|
EV, bln rub |
? |
|
9 104 |
12 425 |
6 340 |
10 974 |
8 630 |
|
7 640 |
|
Book value, bln rub |
|
|
806 |
748 |
914 |
377 |
830 |
|
1 221 |
|
|
EPS, rub |
? |
|
-9.71 |
-7.11 |
-5.15 |
-8.03 |
-5.80 |
|
1.28 |
|
FCF/share, rub |
|
|
-7.05 |
0.32 |
-5.93 |
-4.07 |
-6.37 |
|
-4.93 |
|
BV/share, rub |
|
|
10.9 |
9.60 |
11.2 |
4.31 |
8.98 |
|
12.8 |
|
|
EBITDA margin, % |
? |
|
-171.4% |
-83.9% |
-43.6% |
-62.4% |
-35.3% |
|
9.35% |
|
Net margin, % |
? |
|
-187.8% |
-102.6% |
-59.7% |
-75.4% |
-43.1% |
|
7.43% |
|
FCF yield, % |
? |
|
-5.47% |
0.19% |
-6.58% |
-3.14% |
-6.60% |
|
-6.32% |
|
ROE, % |
? |
|
-87.4% |
-72.7% |
-45.1% |
-182.7% |
-62.4% |
|
9.98% |
|
ROA, % |
? |
|
-39.2% |
-18.6% |
-13.3% |
-22.5% |
-16.4% |
|
3.38% |
|
|
P/E |
? |
|
-13.3 |
-24.0 |
-17.5 |
-16.1 |
-16.6 |
|
61.1 |
|
P/FCF |
|
|
-18.3 |
526.1 |
-15.2 |
-31.9 |
-15.1 |
|
-15.8 |
|
P/S |
? |
|
24.9 |
24.6 |
10.4 |
12.2 |
7.17 |
|
4.54 |
|
P/BV |
? |
|
11.8 |
17.8 |
8.01 |
30.1 |
10.7 |
|
6.09 |
|
EV/EBITDA |
? |
|
-13.9 |
-27.4 |
-20.7 |
-18.9 |
-19.7 |
|
49.8 |
|
Debt/EBITDA |
|
|
0.61 |
1.91 |
3.19 |
0.64 |
0.64 |
|
1.30 |
|
|
R&D/CAPEX, % |
|
|
894.4% |
878.7% |
2 004% |
2 845% |
1 153% |
|
668.3% |
|
|
CAPEX/Revenue, % |
|
|
16.5% |
15.2% |
5.48% |
3.30% |
6.12% |
|
7.19% |
|
| Sarepta Therapeutics shareholders |
